Expertise in
2
conditions

Dr. Susan H. Tannenbaum

Hematology
UConn John Dempsey Hospital
263 Farmington Ave, 
Farmington, CT 
Expertise in
2
conditions
UConn John Dempsey Hospital
263 Farmington Ave, 
Farmington, CT 

Overview

Susan Tannenbaum is a Hematologist practicing medicine in Farmington, Connecticut.

Dr. Tannenbaum is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Venous Thromboembolism (VTE), ALK-Positive Non-Small Cell Lung Cancer, Sickle Cell Disease, and Non-Hodgkin Lymphoma.

She is actively involved in clinical research, co-authoring 21 peer reviewed articles and participating in 6 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in CT

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

UConn John Dempsey Hospital
263 Farmington Ave, Farmington, CT 06030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drugs: ONC-392, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase I Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma
A Phase I Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma
Enrollment Status: Terminated
Publish Date: November 07, 2022
Intervention Type: Biological
Study Phase: Phase 1
Phase II Trial of Abemaciclib and T-DM1 in Women and Men With HER2-positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment With a Taxane, Trastuzumab and Pertuzumab
Phase II Trial of Abemaciclib and T-DM1 in Women and Men With HER2-positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment With a Taxane, Trastuzumab and Pertuzumab
Enrollment Status: Withdrawn
Publish Date: May 26, 2022
Intervention Type: Drug, Biological
Study Drugs: Abemaciclib, Trastuzumab Emtansine
Study Phase: Phase 2
Trial of Vaginal Estrogen for Urogenital Symptom Relief in Women on Aromatase Inhibitors: Systemic Impact Versus Local Objective Benefits and Quality of Life
Trial of Vaginal Estrogen for Urogenital Symptom Relief in Women on Aromatase Inhibitors: Systemic Impact Versus Local Objective Benefits and Quality of Life
Enrollment Status: Completed
Publish Date: September 18, 2017
Intervention Type: Behavioral
Study Phase: Not Applicable
View 5 Less Clinical Trials

21 Total Publications

Racial Disparities in Pathologic Complete Response and Survival after Neoadjuvant Chemotherapy for Breast Cancer.
Racial Disparities in Pathologic Complete Response and Survival after Neoadjuvant Chemotherapy for Breast Cancer.
Journal: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Published: April 11, 2025
Similar Doctors
Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required

UConn John Dempsey Hospital

263 Farmington Ave, 
Farmington, CT 
 (0.1 miles away)
860-679-2100
Languages Spoken:
English
See accepted insurances

Biree Andemariam is a Hematologist practicing medicine in Farmington, Connecticut. Dr. Andemariam is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Yale New Haven Hospital

20 York St, 
New Haven, CT 
 (30.5 miles away)
203-200-4363
Languages Spoken:
English
See accepted insurances

Amer Zeidan is a Hematologist practicing medicine in New Haven, Connecticut. Dr. Zeidan is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
29
conditions
Expertise in
29
conditions
Referral may be required

Smilow Cancer Hospital

35 Park St, 
New Haven, CT 
 (30.5 miles away)
203-200-4363
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nikolai Podoltsev is a Hematologist practicing medicine in New Haven, Connecticut. Dr. Podoltsev is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Myeloproliferative Neoplasms (MPN), Essential Thrombocythemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Susan H. Tannenbaum

How do I make an appointment with Dr. Susan H. Tannenbaum?

You can book an appointment with Dr. Susan H. Tannenbaum by calling their office at 860-679-2100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Susan H. Tannenbaum a top-rated expert for Venous Thromboembolism (VTE)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Susan H. Tannenbaum is classified as an Advanced expert for Venous Thromboembolism (VTE), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Susan H. Tannenbaum specialize in?

While Dr. Susan H. Tannenbaum is a Hematology, they have specific expertise in Venous Thromboembolism (VTE), ALK-Positive Non-Small Cell Lung Cancer, and Sickle Cell Disease. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Susan H. Tannenbaum participate in research or clinical trials?

Yes. Dr. Susan H. Tannenbaum has published 21 articles and abstracts on conditions like Venous Thromboembolism (VTE). You can view a list of Dr. Susan H. Tannenbaum's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Susan H. Tannenbaum accept my insurance?

Dr. Susan H. Tannenbaum accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 860-679-2100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tannenbaum's expertise for a condition
ConditionClose
      View All 15 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile